About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson’s diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson’s program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren’s syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company’s proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York. Address: 430 East 29th Street, New York, NY, United States, 10016
MeiraGTx Holdings plc News and around…
Latest news about MeiraGTx Holdings plc (MGTX) common stock and company :
LONDON and NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to provide an update on the Company’s AAV-hAQP1 Phase 1 AQUAx clinical trial for the treatment of radiation-induced xerostomia (RIX) on Tuesday, December 7, 2021, at 8:00 a.m. ET. MeiraGTx will also host a virtual R&D Day via webcast and conference call that will be held on Wednesday,
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -13.46% and 38.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
LONDON and NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the third quarter ended September 30, 2021 and provided an update on recent progress. During the quarter, MeiraGTx continued to progress the Phase 3 Lumeos Trial of botaretigene sparoparvovec, formerly referred to as AAV5-RPGR, in X-linked retinitis pigmentosa (XLRP) with its partner Janssen Pharmaceutical
LONDON and NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following virtual investor conferences: Barclays Gene Editing & Gene Therapy Summit Corporate presentation: Monday, November 15, 2021, at 2:00 p.m. ET 33rd Annual Piper Sandler Healthcare Conference Fireside chat: available from Monday
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Gainers Biophytis (NASDAQ:BPTS) shares moved upwards by 37.54% to $8.5 during Monday's after-market session. The market value of ...
MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Three Poster Presentations Highlight Versatility and Novelty of MeiraGTx’s Gene Therapy Development Platforms Novel Synthetic Riboswitch Platform Reversibly Regulates Gene Expression to High Dynamic Range and Drives Precise Dose Responsive Activation of Transgene Expression In Vivo LONDON and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced three poster presentations at the European Soc
Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both ...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cortexyme Inc (CRTX), where a total of 24,490 contracts have traded so far, representing approximately 2.4 million underlying shares. That amounts to about 960.3% of CRTX's average daily trading volume over the past month of 255,020 shares..
Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 ...
Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints ...
Gainers Valneva (NASDAQ:VALN) stock increased by 35.65% to $38.05 during Monday's pre-market session. The market ...
This weekend's Barron's cover story features the latest results of the annual Barron's Big Money Poll. Other ...
MeiraGtx is quietly working on a promising new approach to gene therapy. Sizing up the opportunity, pondering the unknowns.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $167.98 per unit.
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 30th. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
Gene therapy is set to become one of the most vital spaces with high prospects in the biotech sector.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $32.44 per unit.
I made 63 bullish calls involving 45 companies in 2019. Here are the winners, the stinkers, and everything in between.
Shareholders in MeiraGTx Holdings plc ( NASDAQ:MGTX ) may be thrilled to learn that the analysts have just delivered a...
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 13.21% and 13.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
The big shareholder groups in MeiraGTx Holdings plc ( NASDAQ:MGTX ) have power over the company. Large companies...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Value ETF (IWN), we found that the implied analyst target price for the ETF based upon its underlying holdings is $188.56 per unit.
MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MeiraGTx Holdings plc (MGTX) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
